Filana Therapeutics Inc.
FLNA | NASDAQ
$0.62
-$0.04 (-5.78%)
At close: Oct 30, 2026, 4:00 PM ET
$0.66
+$0.04 (+5.65%)
Pre-market:
Nov 2, 2026, 7:15 AM ET
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 936K | n/a | n/a | n/a | n/a |
Gross Profit | -936K | n/a | n/a | n/a | n/a |
Operating Income | -95.39M | -141.45M | -105.96M | -80.02M | -32.87M |
Interest Income | 4.62M | 8.51M | 7.83M | 2.78M | 49K |
Pretax Income | -90.97M | -24.34M | -97.22M | -76.25M | -32.39M |
Net Income | -90.97M | -24.34M | -97.22M | -76.25M | -32.39M |
Selling & General & Admin | 67.86M | 71.81M | 16.53M | 11.99M | 8.06M |
Research & Development | 26.59M | 69.64M | 89.42M | 68.03M | 24.81M |
Other Expenses | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 94.45M | 141.45M | 105.96M | 80.02M | 32.87M |
Interest Expense | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 95.39M | 141.45M | 105.96M | 80.02M | 32.87M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 48.3M | 46.33M | 41.93M | 40.2M | 39.41M |
Shares Outstanding (Diluted) | 48.3M | 4.66B | 41.93M | 40.2M | 39.41M |
EPS (Basic) | -1.88 | -0.53 | -2.32 | -1.90 | -0.82 |
EPS (Diluted) | -1.88 | -1.46 | -2.32 | -1.90 | -0.82 |
EBITDA | -90.04M | -141.15M | -105.8M | -80.18M | -31.85M |
EBIT | -90.97M | -142.28M | -107.33M | -81.48M | -32.39M |
Depreciation & Amortization | 936K | 1.13M | 1.53M | 1.3M | 534K |
Add to Watchlist
Select watchlists to add or remove FLNA